The Medical Affairs Team at Liquidia is responsible for providing scientific and clinical expertise to support the development and commercialization of biopharmaceutical products for pulmonary arterial hypertension (PAH). This team engages with healthcare professionals, conducts educational initiatives, and ensures that medical information is accurately communicated, fostering collaboration between research and clinical practice to address unmet patient needs.